## **Core Concept**
Methemoglobinemia is a condition characterized by an abnormal amount of methemoglobin, a form of hemoglobin, in the blood. It can be caused by certain medications, including some local anesthetics. The treatment involves reducing methemoglobin back to normal hemoglobin, often with methylene blue.

## **Why the Correct Answer is Right**
The correct answer, **Prilocaine**, is a local anesthetic known to cause methemoglobinemia as a side effect. This is because prilocaine is metabolized into o-toluidine, which induces the formation of methemoglobin. Methylene blue is a specific antidote for methemoglobinemia, acting by reducing methemoglobin to its normal form, thereby restoring the blood's oxygen-carrying capacity.

## **Why Each Wrong Option is Incorrect**
- **Option A: Lignocaine (Lidocaine)** - While lignocaine is a commonly used local anesthetic, it is not typically associated with methemoglobinemia. Its metabolism does not significantly produce methemoglobin-inducing compounds.
- **Option B: Bupivacaine** - Bupivacaine is another widely used local anesthetic. It is not known for causing methemoglobinemia and is not metabolized into compounds that would induce this condition.
- **Option D: Procaine** - Procaine is an older local anesthetic. It is not commonly associated with methemoglobinemia, and its metabolites do not typically cause this condition.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **prilocaine** is uniquely associated with methemoglobinemia due to its metabolism. This makes it a critical consideration in patients receiving local anesthesia, especially in procedures where methemoglobinemia might be a concern. The use of methylene blue as a treatment is also a critical clinical correlation.

## **Correct Answer: C. Prilocaine**